Dual PPARα/γ agonists that were developed to target hyperlipidaemia and hyperglycaemia in type 2 diabetes patients, caused cardiac dysfunction or other adverse effects as fluid retention and body-weight gain. The gene discussed is PPARA; the disease is hyperlipidemia.